ArticleCureus2026
Bundibugyo Virus Disease Outbreak and Cross-Border Response in the Democratic Republic of the Congo and Uganda, May-June 2026.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bundibugyo virus disease (BVD) is a high-consequence filovirus infection with no approved vaccine or specific therapeutic, making early detection, supportive care, infection prevention, and coordinated public health action essential. This editorial is a rapid narrative synthesis of publicly available outbreak information from the WHO Disease Outbreak News, the Centers for Disease Control and Prevention (CDC) reports, the Uganda Ministry of Health updates, and the WHO African Region situation materials. We prioritized official reports because the event was rapidly evolving and because case counts, contact-tracing indicators, and health-zone classifications were being updated as surveillance and laboratory capacity expanded. This editorial summarizes the May-July 2026 BVD outbreak involving the Democratic Republic of the Congo (DRC) and Uganda and highlights public health lessons for cross-border preparedness. We reviewed official WHO, CDC, Uganda Ministry of Health, and WHO African Region reports, with data reviewed through July 3, 2026. WHO was alerted on May 5, 2026, to a high-mortality illness cluster in Mongbwalu Health Zone, Ituri Province, DRC. The DRC and Uganda declared outbreaks on May 15, 2026, and the WHO determined that the event constituted a public health emergency of international concern. Response measures included surveillance, laboratory expansion, isolation and supportive care, contact tracing, infection prevention and control, safe burial, community engagement, cross-border coordination, and preparation for ethically approved trials of candidate countermeasures. This outbreak shows that border-linked surveillance must be integrated with first-contact facility readiness, health-worker protection, trusted community engagement, continuity of essential services, complete contact follow-up, and trial-ready systems rather than reliance on generic Ebola plans or indiscriminate travel restrictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.